173 filings
Page 2 of 9
SC TO-C
gdeltpa09o y5
6 Oct 20
Information about tender offer
4:05pm
SC TO-C
6679 ykint9s5kfl
5 Oct 20
Information about tender offer
5:13pm
SC14D9C
pd1 wt15mq
5 Oct 20
Written communication relating to third party tender offer
4:43pm
SC14D9C
yxozu9i h5e2
5 Oct 20
Written communication relating to third party tender offer
7:01am
8-K
xl5nyem9ellgq 2yl7
5 Oct 20
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
6:47am
8-K
0cqpx2
4 Aug 20
MyoKardia Reports Second Quarter 2020 Financial Results
4:38pm
8-K
ywsw 6yxtkd4
24 Jun 20
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
n0u7kk c5
14 May 20
MyoKardia Announces Proposed Public Offering of Common Stock
5:24pm
424B5
clhums1tz8a
14 May 20
Prospectus supplement for primary offering
5:18pm
424B5
tsg 4xt8rpa6if9a7
11 May 20
Prospectus supplement for primary offering
5:25pm
8-K
x1zuipe uq
11 May 20
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo
9:26am
8-K
i73f78tydpsx5jso
6 May 20
MyoKardia Reports First Quarter 2020 Financial Results
4:34pm
DEFA14A
23uny 0sxo
24 Apr 20
Additional proxy soliciting materials
4:27pm
DEFA14A
ha8y mu1s
24 Apr 20
Additional proxy soliciting materials
4:27pm
8-K
aaxzqbnzp32g9
30 Mar 20
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten
5:13pm
8-K
eggn9v9s m6n
26 Mar 20
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
8:46am
S-8
srz0oi6g
27 Feb 20
Registration of securities for employees
5:02pm